Maureen E. Thyne Discusses Ruxolitinib's Impact on Myelofibrosis

Video

Maureen E. Thyne, RPA-C, Weill Cornell Medical College, discusses the impact that ruxolitinib (Jakafi) has had on patients with myelofibrosis.

Maureen E. Thyne, RPA-C, Weill Cornell Medical College, discusses the impact that ruxolitinib (Jakafi) has had on patients with myelofibrosis.

Since its approval in December 2011, ruxolitinib has improved not only side effects, but also overall survival and quality of life. Five-year data is expected to be reported later this year.

Recent Videos
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.